Long-term outcomes after retinal artery occlusion
Long-Term Cardiovascular and Cerebrovascular Outcomes After Retinal Artery Occlusion: A Nationwide Study
Using Korea's national health records, this study will see if common medicines — antiplatelet agents, blood thinners, or statins — change long-term heart and stroke risks for people newly diagnosed with retinal artery occlusion.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15000 (estimated) |
| Sex | All |
| Sponsor | Chonnam National University Hospital Academic / other |
| Locations | 1 site (Gwangju, Gwangju) |
| Trial ID | NCT07482228 on ClinicalTrials.gov |
What this trial studies
This nationwide, population-based analysis will identify patients newly diagnosed with central or branch retinal artery occlusion in the Korean National Health Insurance Service database from 2010 through 2024. It will compare long-term cardiovascular and cerebrovascular outcomes such as ischemic stroke and myocardial infarction across treatment groups using prescriptions for antiplatelet agents, anticoagulants, and statins and adjust for comorbidities and demographic factors. The observational design will use administrative claims and diagnostic codes to capture events and treatment exposure with statistical methods to address confounding. Results aim to clarify the epidemiology of RAO and whether specific medical therapies are associated with improved long-term outcomes.
Who should consider this trial
Good fit: People newly diagnosed with retinal artery occlusion in Korea during the 2010–2024 period who do not have a prior RAO diagnosis and do not have giant cell arteritis.
Not a fit: Patients with RAO diagnosed before 2010, those with giant cell arteritis, or people outside the Korean National Health Insurance system are unlikely to be represented and may not benefit directly from the findings.
Why it matters
Potential benefit: If successful, the results could help doctors choose medicines that reduce the risk of stroke and heart attack after retinal artery occlusion.
How similar studies have performed: Previous observational studies have linked RAO to higher risks of ischemic stroke and cardiovascular events, but large nationwide analyses examining the effects of antiplatelet, anticoagulant, or statin use on long-term outcomes are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly diagnosed with retinal artery occlusion Exclusion Criteria: * Patients with a prior diagnosis of retinal artery occlusion before the study period. * Patients diagnosed with giant cell arteritis.
Where this trial is running
Gwangju, Gwangju
- Chonnam National University Hospital — Gwangju, Gwangju, South Korea (Recruiting)
Study contacts
- Principal investigator: Seung Hun Lee, MD, PhD — Chonnam National University Hospital
- Study coordinator: Seung Hun Lee, MD, PhD
- Email: lsh8602@naver.com
- Phone: 82-62-220-6246
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.